Navigation Links
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Date:1/8/2008

BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.

"These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase 2b study of SLx-2101 in hypertension in the third quarter of 2008," said Jim Mahoney, President and CEO of Surface Logix. "We believe that with our demonstrated 24-hour coverage from once daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market."

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor. Other PDE5 inhibitors have traditionally been used to treat erectile dysfunction (ED). SLx-2101 was designed specifically to expand the therapeutic potential of PDE5 inhibition beyond ED into larger cardiovascular markets such as hypertension. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. With its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address.

"To achieve efficacy in cardiovascular disease, your compound has to get into the right tissues," commented Dr. Paul Sweetnam, Chief Scientific Officer at Surface Logix. "By leveraging our deep understanding of how small molecules interact with a variety of lipids and proteins, we succeeded in creating a drug candidate that is able to access PDE5 in cardiovascular tissue in a physiologically meaningful way. These Phase 2a clinical results of SLx-2101 demonstrate the translation of this property into therapeutic activity in hypertensive patients, a first for a PDE5 inhibitor."

The results from the trial provide further confirmation for the Pharmacomer(TM) Technology Platform designed by Surface Logix scientists to engineer specific PK and tissue distribution properties into a molecule while optimizing potency and selectivity. The design of SLx-2101 and its development program were directed to differentiate SLx-2101 from other PDE5 inhibitors based on the combined features of potency and an extended duration of action.

About the trial:

The Phase 2a study of SLx-2101 was a randomized, double-blind, placebo-controlled crossover trial, and was conducted at two centers in Europe. A total of 60 patients with uncontrolled hypertension, who were concurrently taking up to 3 marketed anti-hypertensive medications, received 5 mg or 10 mg oral doses of SLx-2101 once daily for up to 14 days. In addition to showing the safety and tolerability of the compound in these dosing regimens, blood pressure monitoring using standard measures (office seated & standing, central, home, and ambulatory) demonstrated that SLx-2101 caused clinically significant reductions in blood pressure.

About SLx-2101

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor designed specifically to expand the therapeutic potential of PDE5 inhibition beyond erectile dysfunction into larger cardiovascular markets such as hypertension. Clinical experience with SLx-2101 to date, including in ED, confirms its ability to positively impact endothelial function in a wide range of tissues. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. By virtue of its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This superior product profile allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address. Surface Logix is also currently conducting a Phase 2a study of SLx-2101 in secondary Raynaud's disease, a vasospastic condition in which PDE5 inhibition has been shown to have a therapeutic benefit. Preclinical data obtained in models of heart failure suggest that SLx-2101 has potential in this indication as well.

About Surface Logix, Inc.

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior drug-like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, oncologic and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.

Contact:

Leland Webster, Ph.D., M.B.A.

Surface Logix, Inc.

Vice President, Corporate Development

617.746.8520

Media:

Sarah Cavanaugh

MacDougall Biomedical Communications Inc.

scavanaugh@macbiocom.com

781-235-3060


'/>"/>
SOURCE Surface Logix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... & Biochemical Research, Disease Diagnostics), End User (Academic & Research Institutes, ... to their offering. ... , The western blotting market ... 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
(Date:12/5/2016)... 5, 2016   BIOTRONIK today announced the ... study evaluates the safety and feasibility of performing the ... setting. BioMonitor 2 is an insertable cardiac ... placed underneath a patient,s skin to help physicians accurately ... fibrillation is a leading cause of stroke and heart ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... its latest transitional care facility – Avamere Transitional Care of Puget Sound ... foot short-term, post-acute health care center will provide patients recovering from illness or ...
(Date:12/5/2016)... St. Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... effects concussions have on the growing brains of young athletes. Over the course of ... to the head through unique mouth guards. The mouth guards, equipped with special sensors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, ... International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February ... are honored to have Amy E. Herman present at this year’s conference, her ...
Breaking Medicine News(10 mins):